<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775190</url>
  </required_header>
  <id_info>
    <org_study_id>2008-184</org_study_id>
    <nct_id>NCT00775190</nct_id>
  </id_info>
  <brief_title>Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives</brief_title>
  <official_title>Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized control trial of Ortho tricyclen versus Trinessa (generic equivalent) to
      determine if they have similar effects. Women will be randomized to receive either Ortho
      tricyclen or Trinessa oral contraceptives and will be asked to keep a daily dairy of any
      symptoms or bleeding experienced. Once a month, participants will be asked to complete a
      survey.

      The objective is to compare generic oral contraceptives (OCPs) and brand name OCPs with
      respect to side effect profiles including bleeding patterns, mood changes, nausea and
      vomiting, frequency of menstrual cramps, breast tenderness, elevation in blood pressure,
      stroke, blood clots and patient compliance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind randomized controlled trial of Ortho tricyclen™ vs. Trinessa™ (generic
      equivalent) to determine if they have similar effects on bleeding patterns, namely days of
      menstrual flow, amount of bleeding, and intermenstrual bleeding. Women will score these
      parameters using a survey with objective measures for days of bleeding, amount of flow, and
      days of breakthrough bleeding. As secondary outcomes, we will compare the side effect
      profiles of each in regards to nausea, vomiting, breast tenderness, menstrual cramps, mood
      changes, and thromboembolic events.

      Patients will record in their daily diary if one of the outcomes occurs or not. We will
      observe whether the events occur and the number of occurrences within the six month time
      period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unale to recruit , progress report not filed by PI
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Bleeding</measure>
    <time_frame>6 Months</time_frame>
    <description>Measures how light or heavy the menstrual flow on a 1 to 3 Likert scale. (Light, Medium, Heavy).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Breakthrough Bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>Any breakthrough bleeding during reporting period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days of Bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days with bleeding during each menstrual period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects (Nausea)</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days of nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects (Vomiting)</measure>
    <time_frame>6 Months</time_frame>
    <description>Number of episodes of vomitting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects (Breast Tenderness)</measure>
    <time_frame>6 Months</time_frame>
    <description>Incidence of breast tenderness during the study time frame</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects (Mood Changes)</measure>
    <time_frame>6 months</time_frame>
    <description>Self reported changes in mood during each month over the time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects (Menstrual Cramps)</measure>
    <time_frame>6 months</time_frame>
    <description>Intensity of menstrual cramps reported on a 4 point Likert scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects (Incidence of Thromboembolic Events)</measure>
    <time_frame>6 months</time_frame>
    <description>Occurrence of any thromboembolic events during the study time frame.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Ortho tricyclen™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant Randomized to Ortho tricyclen 1 tablet by mouth Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trinessa™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant Randomized to Trinessa 1 tablet by mouth Daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ortho tricyclen</intervention_name>
    <description>brand name oral contraceptive</description>
    <arm_group_label>Ortho tricyclen™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trinessa</intervention_name>
    <description>generic oral contraceptive</description>
    <arm_group_label>Trinessa™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nonsmoker

          -  not pregnant

          -  not planning to become pregnant in the next 6 months

          -  not taking hormonal birth control for at least 3 months previous to entering the study

          -  no history of fibroids

          -  no history of ovarian cysts

          -  no history of dysfunctional uterine bleeding

        Exclusion Criteria:

          -  pregnant

          -  under the age of 18

          -  over the age of 35

          -  history of irregular uterine bleeding

          -  history of ovarian cysts

          -  history of fibroids

          -  history of migraines with aura

          -  history of liver disease

          -  family or personal history of Blood clots (thromboembolism)

          -  mental disabilities

          -  desire to become pregnant in the next six months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances Bechek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2008</study_first_submitted>
  <study_first_submitted_qc>October 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <results_first_submitted>March 3, 2017</results_first_submitted>
  <results_first_submitted_qc>March 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2017</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>John Uckele</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>birth control pills</keyword>
  <keyword>oral contraceptives</keyword>
  <keyword>brand name</keyword>
  <keyword>generic</keyword>
  <keyword>side effects</keyword>
  <keyword>oral contraceptive side effects</keyword>
  <keyword>dysfunctional uterine bleeding</keyword>
  <keyword>pre-menstrual symptoms</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ortho Tricyclen™</title>
          <description>ortho tricyclen: brand name oral contraceptive</description>
        </group>
        <group group_id="P2">
          <title>Trinessa™</title>
          <description>Trinessa: generic oral contraceptive</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ortho Tricyclen™</title>
          <description>ortho tricyclen: brand name oral contraceptive</description>
        </group>
        <group group_id="B2">
          <title>Trinessa™</title>
          <description>Trinessa: generic oral contraceptive</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>target population females ages 18-65</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="21" upper_limit="31"/>
                    <measurement group_id="B2" value="24" lower_limit="21" upper_limit="31"/>
                    <measurement group_id="B3" value="24" lower_limit="21" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Beaumont Health System patient population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Amount of Bleeding</title>
        <description>Measures how light or heavy the menstrual flow on a 1 to 3 Likert scale. (Light, Medium, Heavy).</description>
        <time_frame>6 Months</time_frame>
        <population>Study Terminated with no data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ortho Tricyclen™</title>
            <description>ortho tricyclen: brand name oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Trinessa™</title>
            <description>Trinessa: generic oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Bleeding</title>
          <description>Measures how light or heavy the menstrual flow on a 1 to 3 Likert scale. (Light, Medium, Heavy).</description>
          <population>Study Terminated with no data analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Breakthrough Bleeding</title>
        <description>Any breakthrough bleeding during reporting period.</description>
        <time_frame>6 months</time_frame>
        <population>Study Terminated with no data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ortho Tricyclen™</title>
            <description>ortho tricyclen: brand name oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Trinessa™</title>
            <description>Trinessa: generic oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Breakthrough Bleeding</title>
          <description>Any breakthrough bleeding during reporting period.</description>
          <population>Study Terminated with no data analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Days of Bleeding</title>
        <description>Number of days with bleeding during each menstrual period.</description>
        <time_frame>6 months</time_frame>
        <population>Study Terminated with no data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ortho Tricyclen™</title>
            <description>ortho tricyclen: brand name oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Trinessa™</title>
            <description>Trinessa: generic oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Bleeding</title>
          <description>Number of days with bleeding during each menstrual period.</description>
          <population>Study Terminated with no data analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects (Nausea)</title>
        <description>Number of days of nausea</description>
        <time_frame>6 months</time_frame>
        <population>Study Terminated with no data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ortho Tricyclen™</title>
            <description>ortho tricyclen: brand name oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Trinessa™</title>
            <description>Trinessa: generic oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects (Nausea)</title>
          <description>Number of days of nausea</description>
          <population>Study Terminated with no data analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects (Vomiting)</title>
        <description>Number of episodes of vomitting</description>
        <time_frame>6 Months</time_frame>
        <population>Study Terminated with no data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ortho Tricyclen™</title>
            <description>ortho tricyclen: brand name oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Trinessa™</title>
            <description>Trinessa: generic oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects (Vomiting)</title>
          <description>Number of episodes of vomitting</description>
          <population>Study Terminated with no data analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects (Breast Tenderness)</title>
        <description>Incidence of breast tenderness during the study time frame</description>
        <time_frame>6 Months</time_frame>
        <population>Study Terminated with no data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ortho Tricyclen™</title>
            <description>ortho tricyclen: brand name oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Trinessa™</title>
            <description>Trinessa: generic oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects (Breast Tenderness)</title>
          <description>Incidence of breast tenderness during the study time frame</description>
          <population>Study Terminated with no data analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects (Mood Changes)</title>
        <description>Self reported changes in mood during each month over the time frame.</description>
        <time_frame>6 months</time_frame>
        <population>Study Terminated with no data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ortho Tricyclen™</title>
            <description>ortho tricyclen: brand name oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Trinessa™</title>
            <description>Trinessa: generic oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects (Mood Changes)</title>
          <description>Self reported changes in mood during each month over the time frame.</description>
          <population>Study Terminated with no data analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects (Menstrual Cramps)</title>
        <description>Intensity of menstrual cramps reported on a 4 point Likert scale.</description>
        <time_frame>6 months</time_frame>
        <population>Study Terminated with no data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ortho Tricyclen™</title>
            <description>ortho tricyclen: brand name oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Trinessa™</title>
            <description>Trinessa: generic oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects (Menstrual Cramps)</title>
          <description>Intensity of menstrual cramps reported on a 4 point Likert scale.</description>
          <population>Study Terminated with no data analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects (Incidence of Thromboembolic Events)</title>
        <description>Occurrence of any thromboembolic events during the study time frame.</description>
        <time_frame>6 months</time_frame>
        <population>Study Terminated with no data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ortho Tricyclen™</title>
            <description>ortho tricyclen: brand name oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Trinessa™</title>
            <description>Trinessa: generic oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects (Incidence of Thromboembolic Events)</title>
          <description>Occurrence of any thromboembolic events during the study time frame.</description>
          <population>Study Terminated with no data analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ortho Tricyclen™</title>
          <description>ortho tricyclen: brand name oral contraceptive</description>
        </group>
        <group group_id="E2">
          <title>Trinessa™</title>
          <description>Trinessa: generic oral contraceptive</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early Study termination. No data analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Evie Russell, RN</name_or_title>
      <organization>Beaumont Health System</organization>
      <phone>248-898-5388</phone>
      <email>Evie.Russell@beaumont.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

